Teva Pharmaceutical Industries CEO Kåre Schultz's 2020 pay jumps 36% to $16M

Teva Pharmaceutical Industries reports 2020 executive compensation

By ExecPay News

Published: April 21, 2021

Teva Pharmaceutical Industries reported fiscal year 2020 executive compensation information on April 21, 2021.
In 2020, five executives at Teva Pharmaceutical Industries received on average a compensation package of $6.3M, a 41% increase compared to previous year.
Average pay of disclosed executives at Teva Pharmaceutical Industries
Kåre Schultz, Chief Executive Officer, received $16M in total, which increased by 36% compared to 2019. 64% of Schultz's compensation, or $10M, was in stock awards. Schultz also received $3.1M in non-equity incentive plan, $2M in salary, as well as $669K in other compensation.
Hafrun Fridriksdottir, Executive Vice President, Global Research and Development, received a compensation package of $4.3M, which decreased by 2% compared to previous year. 47% of the compensation package, or $2M, was in stock awards.
Brendan O'Grady, Executive Vice President, North America Commercial, earned $4.1M in 2020, a 19% increase compared to previous year.
Eric Drap, Executive Vice President, Global Operations, received $3.8M in 2020.
Eli Kalif, Chief Financial Officer, earned $3.7M in 2020, a 18016% increase compared to previous year.

Related executives

Kåre Schultz

Teva Pharmaceutical Industries

Chief Executive Officer

Eli Kalif

Teva Pharmaceutical Industries

Chief Financial Officer

Hafrun Fridriksdottir

Teva Pharmaceutical Industries

Executive Vice President, Global Research and Development

Brendan O'Grady

Teva Pharmaceutical Industries

Executive Vice President, North America Commercial

Eric Drap

Teva Pharmaceutical Industries

Executive Vice President, Global Operations

You may also like

Source: SEC filing on April 21, 2021.